Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss™ (lebrikizumab) [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Final Recommendation for Ebglyss™ (lebrikizumab), published on Friday, November 15, 2024 . The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec , for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years of age and older. Lilly Canada stands behind Ebglyss as a first-line biological therapy for the treatment of atopic dermatitis and we remain committed to patients. Access to Ebglyss for new and existing patients with moderate-to-severe AD via LillyPlus ® will not change as we tenaciously pursue options for private and public reimbursement in Canada . We have shared our concerns with the CDA-AMC leadership and believe that the CDA-AMC are applying differential standards to biologic therapies for the treatment of AD that are not founded upon their own requirements. Lilly Canada continues to explore all options to overcome this recommendation. "CDA-AMC's recommendation is inconsistent with all other HTA
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing Quality in Clinical Trials (London, United Kingdom - May 28-29, 2025) [Yahoo! Finance]Yahoo! Finance
- Is Now a Good Time to Buy the Dip in Eli Lilly Stock? [Yahoo! Finance]Yahoo! Finance
- Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance Canada]Yahoo! Finance Canada
- Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance]Yahoo! Finance
- Type 2 Diabetes Pipeline Landscape Research 2024: Comprehensive Insights About 75+ Companies and 80+ Drugs [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- LLY's page on the SEC website